Foundation Medicine
Researchers are planning a clinical trial after four metastatic FGFR2 fusion-positive pancreatic cancer patients responded to FGFR-directed therapy.
Foundation Medicine Nabs Five-Year VA Contract for Tumor Molecular Profiling of Cancer Patients
The national contract covers FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne RNA, and FoundationOne Heme.
Massive Bio, Foundation Medicine Partner to Improve Oncology Clinical Trial Enrollment
The companies will develop integrated solutions that use shared data and AI analytics focused on patient matching to clinical trials.
Foundation Medicine, Syndax Pharmaceuticals Partner to Develop CDx for AML Treatment
The companion diagnostic assay, for a drug under development by Syndax, will identify acute myeloid leukemia patients with an NPM1 mutation.
Foundation Medicine Nets FDA Approval for Tissue, Liquid NGS CDx for Lynparza Combo
The FDA approved FoundationOne CDx and FoundationOne Liquid for identifying BRCA1/2-mutated mCRPC patients eligible for Lynparza, Zytiga, and a steroid.
Jul 24, 2024
Nov 2, 2023